{
    "1721822304533881272": {
        "attachments": {
            "media_keys": [
                "3_1721822302168350720"
            ]
        },
        "author_id": "62465691",
        "created_at": "2023-11-07T09:30:01.000Z",
        "edit_history_tweet_ids": [
            "1721822304533881272"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 24,
                    "normalized_text": "Transthyretin amyloidosis",
                    "probability": 0.8957,
                    "start": 0,
                    "type": "Other"
                },
                {
                    "end": 30,
                    "normalized_text": "ATTR",
                    "probability": 0.5155,
                    "start": 27,
                    "type": "Other"
                },
                {
                    "end": 46,
                    "normalized_text": "cardiomyopathy",
                    "probability": 0.608,
                    "start": 33,
                    "type": "Other"
                },
                {
                    "end": 65,
                    "normalized_text": "polyneuropathy",
                    "probability": 0.7184,
                    "start": 52,
                    "type": "Other"
                },
                {
                    "end": 239,
                    "normalized_text": "ATTR",
                    "probability": 0.5509,
                    "start": 236,
                    "type": "Other"
                }
            ],
            "urls": [
                {
                    "display_url": "learn.az/6015ul26R",
                    "end": 274,
                    "expanded_url": "https://learn.az/6015ul26R",
                    "start": 251,
                    "status": 200,
                    "unwound_url": "https://www.astrazeneca.com/media-centre/articles/2023/detecting-amyloidosis-understanding-the-different-types-of-attr.html?utm_source=twitter&utm_medium=evergreen+attr+campaign+-+q4+2023&utm_term=12105&utm_content=cvrm",
                    "url": "https://t.co/nXQ9S5AMdu"
                },
                {
                    "display_url": "pic.twitter.com/YFWj4tRd6V",
                    "end": 298,
                    "expanded_url": "https://twitter.com/AstraZeneca/status/1721822304533881272/photo/1",
                    "media_key": "3_1721822302168350720",
                    "start": 275,
                    "url": "https://t.co/YFWj4tRd6V"
                }
            ]
        },
        "id": "1721822304533881272",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 3935,
            "like_count": 9,
            "quote_count": 0,
            "reply_count": 1,
            "retweet_count": 2
        },
        "text": "Transthyretin amyloidosis (ATTR) cardiomyopathy and polyneuropathy can cause symptoms such as fatigue, exercise intolerance and sensory deficits, which mimic symptoms of other, more common diseases. \n\nLearn more about managing care for ATTR patients: https://t.co/nXQ9S5AMdu https://t.co/YFWj4tRd6V"
    }
}